{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059817","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.007982+00:00","generated_at":"2026-06-15T02:25:09.467160+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Carisma Therapeutics Q1 net loss widens to $24.6M; cash post-merger $139M","bullets":["Net loss of $24.6M in Q1 2023, vs $11.3M in Q1 2022, driven by higher R&D and G&A expenses.","Cash, cash equivalents and marketable securities of $139.0M as of March 31, 2023, vs $52.0M at Dec 31, 2022.","Merger with Sesen Bio closed; net assets acquired $80.3M, concurrent financing raised $30.6M.","Initiated Phase 1 sub-study of CT-0508 + KEYTRUDA; IND for CT-0525 expected H2 2023.","R&D expenses $16.6M (up from $8.8M) and G&A expenses $9.6M (up from $2.2M) vs prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059817","json":"https://secwatch.observer/filing/0001104659-23-059817.json","markdown":"https://secwatch.observer/filing/0001104659-23-059817.md","text":"https://secwatch.observer/filing/0001104659-23-059817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923059817/0001104659-23-059817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923059817/tm2315501d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:25:09.467160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd3b070039c71199db21369e06f640a5a192bd62","claim":"Carisma Therapeutics Inc. reported first quarter ended March 31, 2023 results: net income Net loss was $24.6 million for the first quarter of 2023.","evidence_excerpt":"Net loss was $24.6 million for the first quarter of 2023, compared to net loss of $11.3 million for the same period in 2022, primarily due to increased research and development expenses, which was partially offset by Moderna collaboration revenue.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923059817/0001104659-23-059817-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $24.6 million for the first quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}